Navigation Links
FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
Date:7/29/2013

WASHINGTON, July 29, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing and granted a priority review classification to Vanda's New Drug Application (NDA) for tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.

The FDA grants priority review status for a "drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness" over current therapies[1].  Currently, there is no approved treatment for Non-24 and tasimelteon has the potential to address this unmet medical need.

"We are extremely pleased that the FDA has granted tasimelteon priority review for the treatment of Non-24 in the totally blind," said Mihael H. Polymeropoulos M.D., Vanda's President and Chief Executive Officer.  "The agency's acceptance of the NDA and decision to place tasimelteon in a category of expedited review are important milestones for Vanda as we take another step toward our goal of providing patients with a treatment for Non-24."

The FDA determined the action target date under Prescription Drug User Fee Act (PDUFA-V), to be January 31, 2014.  The FDA has also tentatively scheduled an advisory committee meeting to discuss the tasimelteon application on November 14, 2013.

About Non-24-Hour Disorder
Non-24 is a serious, rare, and chronic circadian rhythm disorder characterized by the inability to entrain (synchronize) the master body clock with the 24-hour day-night cycle.  Non-24 affects a majority of totally blind individuals, or between 65,000 and 95,000 people in the U.S.  Non-24 occurs almost entirely in individuals who lack the light sensitivity ne
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
2. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
3. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
4. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
5. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
6. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
7. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
8. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
9. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
10. EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications
11. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015   ... to eliminate all preventable hospitalization, recently received confirmation ... its Remote Patient Intelligence (RPI) solution meets the ... FDA intends to exercise "Enforcement Discretion." ... not subject to further FDA regulatory requirements at ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, ... delivery platforms, has received Orphan Drug Designation from ... second drug product that uses NanoSmart,s proprietary drug ... of dactinomycin for the treatment of Ewing,s sarcoma, ... FDA granted NanoSmart,s Orphan Drug Designation on the ...
(Date:7/30/2015)... 30, 2015  Cleave Biosciences today announced that ... granted the company a key patent providing the ... CB-5083. This newly issued patent, "Fused ... U.S. 9,062,026, allows for claims on the composition ... oral inhibitor of p97, a critical enzyme that ...
Breaking Medicine Technology:FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 27 VirtualScopics, Inc. (Nasdaq: VSCP ), a ... announced that before the market opens on Thursday, November ... financial results. The company will host a conference call ... President and Chief Executive Officer, Jeff Markin, and Chief ...
... ARAY ), a global leader in the field of ... installed base has signed on to utilize Accuray,s Treatment Planning ... 10 percent of U.S. sites that had signed ... is designed to help customers maximize utilization of their CyberKnife ...
Cached Medicine Technology:VirtualScopics Schedules Third Quarter 2009 Earnings Announcement 2Accuray's Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers 2Accuray's Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers 3Accuray's Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... New Tool That Increases Training Capability , World renown body weight ... Zejax ( http://www.Zejax.com ), that dramatically increases a person’s training capability. , The ...
(Date:7/30/2015)... ... July 30, 2015 , ... Using the latest online ... teach people more effective ways to prevent and manage major depression. , “Suicide is ... enough, so people fall through the cracks and die needlessly everyday,” says Walker. “I’m ...
(Date:7/30/2015)... ... ... On July 23rd Clay Today Online reported the state of Florida ... system, which has amassed largely enough throughout the years. Florida is the third state ... recent reduction of non violent drug offender’s prison sentences, Florida is beginning to take ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Ocean Hills ... available, including the very rare “no recommendations.” No recommendations means CARF found no areas ... is a notation that less than 3% of all facilities receive. In addition, Ocean ...
(Date:7/30/2015)... Newark, NJ (PRWEB) , ... July 30, 2015 ... ... New Jersey's State-designated entity on behalf of the New Jersey Department of Health, ... for Health Information Technology, an agency of the U.S. Department of Health and ...
Breaking Medicine News(10 mins):Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2
... Reporter , WEDNESDAY, Nov. 17 (HealthDay News) -- An ... to have passed an initial hurdle by proving safe ... designed to look at safety, researchers scheduled to present ... meeting in Chicago also report that anacetrapib raised HDL ...
... News) -- The U.S. Food and Drug Administration on Wednesday ... illegal. In warning letters to the companies, the agency ... "unsafe food additive," and the companies risked further action, including ... for the claim that the addition of caffeine to these ...
... named Walter and Eliza Hall Institute researcher Dr Benjamin Kile ... Minister,s Prize for Life Scientist of the Year is awarded ... the potential to advance, human welfare. Dr Kile, ... be presented with the award tonight by the Hon. Kim ...
... Institute of Public Health (NIPH) shows that children with severe ... 18 months of age compared to healthy children. Children with ... not show an increased risk of anxiety. - ... heart defects are prone to emotional problems at a very ...
... not have a chance to fight health problems if ... Non-adherence to medications costs thousands of lives and billions ... according to the New England Healthcare Institute. Now, researchers ... strategy that is three times more effective than previously ...
... that patients suffering back pain get quicker diagnosis and ... Traditionally, patients face long and anxiety-ridden wait times - ... by a spine surgeon. Results from the year long ... a Nurse Practitioner were significantly shorter, ranging from 10 ...
Cached Medicine News:Health News:Experimental Drug Raises Good Cholesterol Levels in Early Trial 2Health News:Experimental Drug Raises Good Cholesterol Levels in Early Trial 3Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 3Health News:Dr. Benjamin Kile named 2010 Australian Life Scientist of the Year 2Health News:Doubled risk of anxiety for 18 month-old children with congenital heart defects 2Health News:Researchers fight America's 'other drug problem' 2Health News:Toronto Western Hospital study demonstrates improved wait times for patients suffering back pain 2
... HCFA Evaluation and Management guidelines in selecting billing ... information, it calculates the HCFA scores for each ... the effect of changing different parts of the ... you entered to create an audit trail of ...
... Coder is simply more than ... a handheld solution for accurate ... both individual physicians and small ... now comes in three versions ...
... is a computerized medical reference ... encompasses a wide array of ... sets and decision tree analysis ... medical educators, nurses and health ...
... mobileMICROMEDEX™ gives physicians, ... professionals reliable clinical information ... confirm treatment decisions. Clinicians ... in mobileMICROMEDEX because all ...
Medicine Products: